$UCBJY News

Last published 3y ago

3y agoUCBJYUCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023PR NewswireResults from the Phase 3 studies evaluating impact of bimekizumab on pain and health-related quality of life in moderate-to-severe hidradenitis suppurativa will be shared in two oral presentationsATLANTA, Oct. 13, 2023
3y agoUCBJYPhase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis SuppurativaPR NewswireBimekizumab treatment resulted in clinically meaningful improvements in HiSCR50 and the more stringent endpoints HiSCR75, HiSCR90 and HiSCR100 vs. placebo at Week 16, with improvements increasing for patients remaining
3y agoUCBJYUCB presents late-breaking posters at Child Neurology Society MeetingPR NewswireATLANTA, Oct. 4, 2023 /PRNewswire/ -- The Child Neurology Society Meeting, a prominent event in the field of pediatric neurology, is set to showcase cutting-edge research and developments in child neurology. As part of
3y agoUCBJYUCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.PR NewswireRYSTIGGO is now commercially available by prescription in the United States for adult patients with gMG who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive1RYSTIGGO
3y agoUCBJYUCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravisPR NewswireFDA approval of RYSTIGGO® (rozanolixizumab-noli) has been granted under the Priority Review designation for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor
3y agoUCBJYUCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual MeetingPR NewswireNew insights from leading portfolio demonstrate ongoing commitment to improving outcomes and experiences of those living with epilepsy and rare epileptic syndromesData will showcase further insights into the potential of
3y agoUCBJYUCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled SubstancePR NewswireATLANTA, April 17, 2023 /PRNewswire/ -- UCB (Euronext: UCB), a global biopharmaceutical company, today announced the U.S. Drug Enforcement Administration (DEA) has published a final rule stating that FINTEPLA oral
3y agoUCBJYBimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 WeeksPR NewswirePatients treated with investigational bimekizumab, an IL-17A and IL-17F inhibitor, achieved statistically significant and clinically meaningful improvements over placebo in signs and symptoms of hidradenitis suppurativa
3y agoUCBJYUCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis SuppurativaPR NewswirePhase 3 data on investigational bimekizumab in the treatment of adults with moderate to severe hidradenitis suppurativa to be presented as a late-breaking platform presentationBRUSSELS and ATLANTA, March 16, 2023
3y agoUCBJYAnnals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial SpondyloarthritisPR NewswirePublication of 24-week results from the BE MOBILE 1 and BE MOBILE 2 studies, evaluating bimekizumab, an IL-17A and IL-17F inhibitor, across the full spectrum of axial spondyloarthritisBRUSSELS and ATLANTA, Jan. 18, 2023
3y agoUCBJYUCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority ReviewPR NewswireBiologic License Application (BLA) designated Priority Review by FDA and seeks approval for rozanolixizumab for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetycholine receptor (AChR)
3y agoUCBJYUCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis SuppurativaPR NewswireTop-line results show that the two Phase 3 studies, BE HEARD I and BE HEARD II, met their primary and key secondary endpoints with statistical significance and consistent clinical relevanceFirst Phase 3 evidence to
3y agoUCBJYThe Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic ArthritisPR NewswireTwo articles report results from the Phase 3 BE OPTIMAL and BE COMPLETE studies evaluating bimekizumab, an investigational, selective inhibitor of IL-17A and IL-17F, in patients with psoriatic arthritisBRUSSELS and
3y agoUCBJYUCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy carePR Newswire21 scientific presentations, including 7 late breakers, showcase the breadth of UCB's portfolio, reinforcing commitment to improving the lives of people living with epilepsyNew data include insights into the efficacy
3y agoUCBJYEpilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)PR NewswirePeer-reviewed results from the Phase 3 open-label extension study of FINTEPLA® in LGS provide significant reduction in the frequency of multiple seizure types associated with a drop or fall for 15 months, including
3y agoUCBJYUCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patientsPR NewswireNew drug application (NDA) for zilucoplan seeks approval for the treatment of generalized myasthenia gravis (gMG) in adult patients who are acetylcholine receptor antibody positive (AChR-Ab+)Acceptance by U.S. Food and
4y agoUCBJYBimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing SpondylitisPR NewswireNew late-breaking 52-week data from Phase 3 bimekizumab investigational studies in psoriatic arthritis and across the spectrum of axial spondyloarthritis, including non-radiographic axial spondyloarthritis and ankylosing
4y agoUCBJYUCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022PR NewswireLate-breaking 52-week data on investigational bimekizumab in the treatment of adults with active psoriatic arthritis and active axial spondyloarthritis to be presentedNew data on CIMZIA® (certolizumab pegol) and
4y agoUCBJYUCB U.S. HEADQUARTERS IN ATLANTA AWARDED PRESTIGIOUS LEED GOLD AND WELL PLATINUM CERTIFICATIONSPR NewswireUCB's Atlanta Warehouse is the first dually certified WELL Platinum and LEED Gold pharmaceutical project in the world and the first WELL Platinum building in Georgia Together, the premier standards for green building and enhancing people's health and w
4y agoUCBJYUCB presents latest data from generalized myasthenia gravis portfolio at AANEM meetingPR NewswireResults presented across UCB's generalized myasthenia gravis (gMG) development program builds the body of evidence around the complexities of gMG Presentations to include data from the Phase 3 MycarinG study of rozanolixizumab as well as the Phase 3 RA
4y agoUCBJYNew Three-Year Bimekizumab Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque PsoriasisPR NewswireThree-year data from the BE BRIGHT open-label extension study are being presented at the 31st EADV Congress Over eight out of 10 patients who achieved complete skin clearance (PASI 100) at week 16 maintained PASI 100 responses and health-related qualit
4y agoUCBJYUCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV CongressPR Newswire20 abstracts highlight research in key disease areas including psoriasis and psoriatic arthritis New three-year data to be presented on bimekizumab in the treatment of moderate to severe plaque psoriasis BRUSSELS and ATLANTA, Sept. 1, 2022 /PRNewswir
4y agoUCBJYFirst Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022PR NewswireNew data from BE MOBILE 1 and BE MOBILE 2 show that bimekizumab achieved consistent improvements versus placebo in signs and symptoms across the full spectrum of axial spondyloarthritis (axSpA), including non-radiographic axSpA (nr-axSpA) and ankylosing
4y agoUCBJYUCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022PR NewswireFirst presentations from the BE OPTIMAL and BE COMPLETE studies evaluating bimekizumab in the treatment of adults with active psoriatic arthritis who were biologic-naïve and TNF-inadequate responders, respectively A higher proportion of patients treat
4y agoUCBJYUCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravisPR NewswirePhase 3 RAISE and MycarinG studies in generalized myasthenia gravis (gMG) show zilucoplan and rozanolixizumab improve gMG-specific outcomes with consistent statistical significance and clinical relevance Regulatory submissions for zilucoplan and rozano
4y agoUCBJYJAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS)PR NewswirePrimary endpoint was met demonstrating that FINTEPLA, as adjunctive treatment, is effective in significantly reducing the frequency of drop seizures in LGS patients compared to placebo1 The peer-reviewed published data reinforce the clinical profile of
4y agoUCBJYUCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual MeetingPR NewswireScientific presentations illustrate UCB's commitment to addressing unmet needs of people living with a broad range of serious neurological diseases New data focused on epilepsy and Parkinson's disease (PD), including real-world use of BRIVIACT® (briva
4y agoUCBJYFINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)PR NewswireFINTEPLA® has demonstrated efficacy in the most difficult-to-treat seizure types,1,2 including drop seizures, which cause a person to suddenly lose muscle tone, become limp, and fall to the ground, with a high likelihood of injury3 LGS is a severe chi
4y agoUCBJYNew Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual MeetingPR NewswireEleven abstracts highlight new data on bimekizumab in the treatment of adults with moderate to severe plaque psoriasis Pooled data from five Phase 3/3b trials showed that more than eight out of 10 patients who achieved complete skin clearance with bime
4y agoUCBJYUCB announces positive data in myasthenia gravis with zilucoplan phase 3 study resultsPR NewswireBRUSSELS and ATLANTA, Feb. 4, 2022 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive topline results from the RAISE (NCT04115293) triali evaluating its investigational treatment zilucoplan, a self-administered, subcutane
4y agoUCBJYPositive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis StudyPR NewswireBRUSSELS and ATLANTA, Jan. 21, 2022 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive top-line results from the Phase 3 BE COMPLETE study, which evaluated the efficacy and safety of bimekizumab in the treatment of adults w
4y agoUCBJY ZGNXUCB to acquire ZogenixPR NewswireBRUSSELS and EMERYVILLE, Calif., Jan. 19, 2022 /PRNewswire/ -- Regulated information – Inside information – UCB (Euronext: UCB) and Zogenix (NASDAQ:ZGNX) announced today that the companies have entered into a definitive agreement under which UCB wou
4y agoUCBJYPositive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis StudyPR NewswireBRUSSELS and ATLANTA, Jan. 18, 2022 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive top-line interim analysis results showing that the Phase 3 BE MOBILE 1 study met the primary and all ranked secondary endpoints.1 BE M
4y agoUCBJYPositive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis TrialPR NewswireBRUSSELS and ATLANTA, Dec. 16, 2021 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive top-line interim analysis results from the Phase 3 BE MOBILE 2 study, which is evaluating the efficacy and safety of bimekizumab in ad
4y agoUCBJYUCB to present new data at the American Epilepsy Society 75th Annual Meeting 2021, reinforcing long-standing commitment to advancing epilepsy treatment and carePR NewswireBRUSSELS and ATLANTA, Dec. 3, 2021 /PRNewswire/ -- 1:30 p.m. ET: UCB today announced that new data from its seizure treatment portfolio (BRIVIACT, NAYZILAM, and VIMPAT) will be showcased at the 75th American Epilepsy Society Annual Meeting (Chicago, I
4y agoUCBJYUCB Announces Global Partnership To Bring Disease-Modifying Therapies To People Living With Parkinson's DiseasePR NewswireBRUSSELS, Dec. 2, 2021 /PRNewswire/ -- UCB today announced that it has entered into a global co-development and co-commercialization agreement with Novartis covering UCB0599, a potential first in class, small molecule, alpha-synuclein misfolding inhibito
4y agoUCBJYPositive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin SymptomsPR NewswireBRUSSELS and ATLANTA, Nov. 19, 2021 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive top-line interim analysis results from the Phase 3 BE OPTIMAL study assessing the efficacy and safety of bimekizumab, a dual IL-17A and
5y agoUCBJYUCB Showcases Key Rheumatology Data at ACR Convergence 2021PR NewswireATLANTA, Nov. 5, 2021 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced new data on its investigational IL-17A and IL-17F inhibitor, bimekizumab, and its TNF inhibitor, CIMZIA® (certolizumab pegol). Eleven abstracts are being pre
5y agoSHCR UCBJYSharecare and UCB to present on future of decentralized clinical research at 2021 CNS SummitPR NewswireATLANTA, Nov. 3, 2021 /PRNewswire/ -- Sharecare (NASDAQ:SHCR), the digital health company that helps people manage all their health in one place, today announced that it will co-present with global biopharmaceutical company UCB at the 12th annual CNS Su
5y agoUCBJYUnique Patient-led and Co-authored Analysis of the Experience of Living with Myasthenia Gravis Published in Neurology and TherapyPR NewswireBRUSSELS and ATLANTA, Oct. 27, 2021 /PRNewswire/ -- A new, patient-led research analysis published this week in the journal Neurology and Therapy reveals the lived experience of myasthenia gravis (MG) and calls for greater understanding of the reality o
5y agoUCBJYUCB to license its AI technology that improves identification of Osteoporosis to ImageBiopsy LabPR NewswireBRUSSELS and ATLANTA, Oct. 20, 2021 /PRNewswire/ -- UCB today – on World Osteoporosis Day 2021 – announced a strategic out-licensing of Artificial Intelligence (AI) based fracture identification technology, BoneBot, to ImageBiopsy Lab to bring the
5y agoUCBJYUpdate on U.S. FDA Review of Biologics License Application (BLA) for bimekizumabPR NewswireBRUSSELS and ATLANTA, Oct. 16, 2021 /PRNewswire/ -- Regulated Information – Inside Information – UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that they were unable
5y agoUCBJYNew Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology CongressPR NewswireBRUSSELS and ATLANTA, Sept. 29, 2021 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced new interim results from the BE BRIGHT open-label extension (OLE) study evaluating the long-term safety, tolerability and efficacy of bimekizuma
5y agoUCBJYUCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and OlderPR NewswireATLANTA, Aug. 30, 2021 /PRNewswire/ -- UCB announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for BRIVIACT (brivaracetam) CV tablets, oral solution, and injection to treat partial-onset seizures in patien
5y agoUCBJY"The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque PsoriasisPR NewswireBRUSSELS, April 23, 2021 /PRNewswire/ -- UCB, a global biopharmaceutical company, announced today that The New England Journal of Medicine has published two manuscripts with results from BE RADIANT and BE SURE, two Phase 3 studies evaluating the efficac
5y agoUCBJYUCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021PR NewswireBRUSSELS, April 23, 2021 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that 12 abstracts on bimekizumab, an investigational IL-17A and IL-17F inhibitor, in the treatment of adults with moderate to severe plaque psoriasis, will